Abstract

Methods We describe a case of a 13 yo girl diagnosed with ADHD since early childhood, in MP use for the past 3 years. She complained about a mild discomfort of proximal muscles of the lower limbs and cramps for the previous 3 months. Routine exams revealed increased aminotransferases levels (AST 192 UI/L; ALT 222 UI/L), suggesting hepatotoxicity. New laboratory tests were ordered, showing a CPK level of 18300 UI/L, AST 393 and ALT 330. The MP use became intermittent while the investigation was performed. Two weeks later, AST was 80 and ALT 166. A thorough investigation showed negative viral serology (HAV, HBV, HCV, HIV, CMV and EBV); negative autoantibodies (FAN, anti-LKM, anti-smooth muscle, anti-TPO and anti-tireoglobulin); normal hemogram; negative inflammatory markers (ESR and PCR) and a normal lower limbs MRI. An ECG revealed an altered antero-septal repolarization and echocardiogram was normal. Twenty days after, a new lab evaluation revealed a decreasing level of CPK (9670). One month after the complete withdrawal of the MP, the myalgia and cramps were no more present and CPK levels decreased to 3160mg/dl.

Highlights

  • From 2011 Pediatric Rheumatology Symposium sponsored by the American College of Rheumatology Miami, FL, USA. 2-5 June 2011

  • Methylphenidate (MP) (Ritalin®, Concerta®) is a drug commonly used for the treatment of children affected by attention-deficit hyperactivity disorder (ADHD)

  • We describe a case of a 13 yo girl diagnosed with ADHD since early childhood, in MP use for the past 3 years

Read more

Summary

Introduction

Methylphenidate (MP) (Ritalin®, Concerta®) is a drug commonly used for the treatment of children affected by attention-deficit hyperactivity disorder (ADHD). From 2011 Pediatric Rheumatology Symposium sponsored by the American College of Rheumatology Miami, FL, USA. Purpose Methylphenidate (MP) (Ritalin®, Concerta®) is a drug commonly used for the treatment of children affected by attention-deficit hyperactivity disorder (ADHD). Literature shows some cases of cardiovascular side-effects, including arrhythmia and sudden death, but we failed to find a report of associated skeletal-muscle manifestation.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.